Apoptosis slowing

Apoptosis slowing refers to the biological process of inhibiting or delaying programmed cell death, which is a fundamental mechanism for maintaining tissue homeostasis (Elmore, 2007). It is not a specific molecular target, such as a receptor or enzyme, but rather a physiological outcome or therapeutic effect mediated by various signaling pathways. In oncology, the slowing of apoptosis is a recognized hallmark of cancer, where malignant cells evade death signals to survive and proliferate despite cellular stress or DNA damage (Hanahan & Weinberg, 2011). Conversely, in conditions like neurodegenerative diseases or ischemic injury, slowing apoptosis is a primary therapeutic objective intended to protect and preserve functional cells (Mattson, 2000). Key molecular regulators that contribute to this effect include the BCL-2 family of proteins and Inhibitors of Apoptosis Proteins (IAPs). Because this term describes a broad biological phenomenon rather than a single druggable entity, it is classified as an incorrect or non-specific target name in a pharmacological context.

Other names

Apoptosis inhibitionAnti-apoptotic activityProgrammed cell death suppressionCell death delay

Not applicable; this is a biological process/effect rather than a specific molecular target.